RhumbLine Advisers
NVIV

RhumbLine Advisers’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History

RhumbLine Advisers’s Portfolio NVIV Stock Details NVIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-2
Closed -$140K – 2992
2017
Q1 		$140K Hold
2
– – ﹤0.01% 2734
2016
Q4 		$139K Hold
2
– – ﹤0.01% 2758
2016
Q3 		$264K Hold
2
– – ﹤0.01% 2543
2016
Q2 		$223K Buy
2
+1
+100% +$118K ﹤0.01% 2686
2016
Q1 		$176K Hold
1
– – ﹤0.01% 2775
2015
Q4 		$182K Hold
1
– – ﹤0.01% 2833
2015
Q3 		$198K Hold
1
– – ﹤0.01% 2793
2015
Q2 		$354K Buy
+1
New +$264K ﹤0.01% 2549

Other funds holding NVIV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WF
Welch & Forbes Boston, Massachusetts $7.73B AUM 14.94% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ICM
IMS Capital Management Portland, Oregon $217M AUM 18.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RhumbLine Advisers's NVIV Position: Q2 2017 in Review

RhumbLine Advisers sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q2 2017, closing a stake of 2 shares — an estimated $140K sold.

RhumbLine Advisers first reported a position in NVIV in Q2 2015 and held it in 8 quarters. The position peaked at $354K in Q2 2015. 37 funds tracked by Wall St. Rank hold NVIV as of Q2 2017.

  • RhumbLine Advisers reported no remaining InVivo Therapeutics Holdings Corp position as of Q2 2017 after selling out during the quarter.
  • RhumbLine Advisers sold 2 InVivo Therapeutics Holdings Corp shares in Q2 2017, an estimated $140K.
  • RhumbLine Advisers first reported a position in InVivo Therapeutics Holdings Corp in Q2 2015 and held it in 8 quarters.
  • RhumbLine Advisers's InVivo Therapeutics Holdings Corp position peaked at $354K in Q2 2015.
  • 37 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q2 2017.

Based on RhumbLine Advisers's 13F filing for Q2 2017, filed 2 Aug 2017.